PCDHA13

Across TCGA pan-cancer cohorts, PCDHA13 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PCDHA13 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCDHA13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHA13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

LUAD, UCEC, and LIHC are the cancer types where PCDHA13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.265	0.669	<.001	21	view →
UCEC	OS	Median	All	0.961	0.639	.005	14	view →
LIHC	DFS	Median	II,III,IV	0.060	0.417	<.001	9	view →
SKCM	DFS	Median	III,IV	0.187	0.569	.005	8	view →
PRAD	DFS	Median	All	0.617	0.886	.027	6	view →
ESCA	OS	Median	III,IV	0.136	0.573	.037	6	view →
HNSC	DFS	Median	III,IV	0.150	0.598	.003	5	view →
BRCA	OS	Median	II,III,IV	0.830	0.958	.033	4	view →
COAD	DFS	Median	IV	0.718	0.255	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PCDHA13–LUAD (DFS)

Open the LUAD breakdown →